ALX Oncology’s (ALXO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock.

ALXO has been the subject of several other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. Jefferies Financial Group upgraded ALX Oncology from a “hold” rating to a “buy” rating and raised their target price for the stock from $2.00 to $3.00 in a research report on Thursday. UBS Group cut their target price on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Finally, Piper Sandler raised their price target on ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $4.14.

ALX Oncology Price Performance

ALX Oncology stock opened at $1.06 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a market capitalization of $55.91 million, a PE ratio of -0.36 and a beta of 1.01. ALX Oncology has a one year low of $0.95 and a one year high of $17.83. The business has a 50 day simple moving average of $1.39 and a 200 day simple moving average of $1.62.

Institutional Investors Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of ALX Oncology by 12.0% in the 4th quarter. Bank of New York Mellon Corp now owns 90,003 shares of the company’s stock valued at $150,000 after buying an additional 9,623 shares during the period. JSF Financial LLC acquired a new stake in shares of ALX Oncology in the 4th quarter valued at $29,000. Wellington Management Group LLP increased its stake in shares of ALX Oncology by 15.2% in the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after buying an additional 22,114 shares during the period. Northern Trust Corp increased its stake in shares of ALX Oncology by 7.3% in the 4th quarter. Northern Trust Corp now owns 343,066 shares of the company’s stock valued at $573,000 after buying an additional 23,324 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of ALX Oncology by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 740,106 shares of the company’s stock valued at $1,236,000 after buying an additional 39,259 shares during the period. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.